Showing 5441-5450 of 5771 results for "".
- Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAOhttps://modernod.com/news/aura-biosciences-to-present-phase-1b-2-clinical-data-for-au-011-at-aao/2479786/Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- RightEye Eye-Tracking System Receives FDA 510(k) Clearancehttps://modernod.com/news/righteye-eye-tracking-system-receives-fda-510k-clearance/2479799/RightEye announced that the company’s vision system has received 510(k) clearance from the FDA. The system records, views, and analyzes eye movements in support of identifying visual tracking impairment in patients. Using advanced eye-tracking technology and analytics, the RightEye s
- Alcon Expands Surgical Offerings with Portfolio of Mydriatic, Cycloplegic, Diagnostic, and Anesthetic Productshttps://modernod.com/news/alcon-expands-surgical-offerings-with-portfolio-of-mydriatic-cycloplegic-diagnostic-and-anesthetic-products/2479801/Alcon announced that it is expanding its surgical offerings with the addition of a group of products fundamental to many ophthalmic procedures done in the clinic and operating room. These products, which include mydriatic, cycloplegic, diagnostic, and anesthetic products, were transferred from Al
- Vision Ophthalmology Group Acquires MED Medical Products GmbHhttps://modernod.com/news/vision-ophthalmology-group-acquires-med-medical-products-gmbh/2479803/Vision Ophthalmology Group (VOG) has announced the acquisition of MED Medical Products, effective immediately. Terms of the deal were not disclosed. Karlstein, Germany-based MED is a specialist producer of customized procedure packs and disposable products used in ophthalmic surgery
- Zeiss Receives FDA Approval for ReLEx SMILE for Myopia With Astigmatismhttps://modernod.com/news/zeiss-receives-fda-approval-for-astigmatism-indication-for-relex-smile/2479812/Zeiss announced the FDA premarket approval for ReLEx SMILE to treat myopia with astigmatism. The premarket approval also provides for a small entry incision to be made, allowing the
- Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-dosing-of-fourth-cohort-in-phase-1-trial-of-rgx-314-gene-therapy-for-wet-amd/2479815/Regenxbio announced it has completed dosing of the fourth cohort of six patients in a phase 1 clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (AMD). A total of 24 subjects have been dosed in the trial. The company also announced that an updated summary
- Ophthotech Completes Patient Recruitment for Its Phase 2b Clinical Trial of Zimura for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/ophthotech-completes-patient-recruitment-for-its-phase-2b-clinical-trial-of-zimura-for-geographic-atrophy-secondary-to-dry-amd/2479816/Ophthotech announced completion of patient recruitment for its phase 2b clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). Complement factor C5
- Ziemer USA Sponsors Visionary Leader Award at OWL Meetinghttps://modernod.com/news/ziemer-usa-sponsors-visionary-leader-award-at-owl-meeting/2479819/Ziemer USA has announced it is sponsoring the Visionary Leader award, presented at the OWL Signature Event and Awards Ceremony. The OWL (Ophthalmic World Leaders) Visionary Leader award honors an individual who has pa